Question about Residual Disease
I finished Kadcyla this past April. My original diagnosis was October 2021, triple positive, Stage 2, pathogenic ATM gene variant. Started chemo (first Taxotere then Taxol (every week) plus Herceptin and Perjeta (every 3 weeks). Mastectomy in March 2022. There was residual disease so I had to start Kadcyla in June (waited a month or so after DIEP flap reconstruction and then recovering from infection).
So I have a few questions because I'm still not clear. Why do some women still have residual disease and others don't? Does being triple positive make it less likely to have a complete pathological response? (Although I know someone who did have a complete response and is also triple positive). Does the chemo regimen before surgery make a big difference?
I'm just worried. Thanks.